Johnson & Johnson (NYSE:JNJ) Releases Earnings Results, Beats Expectations By $0.18 EPS

Johnson & Johnson (NYSE:JNJ) released its quarterly earnings results on Tuesday. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18, Zacks reports. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson updated its FY 2025 guidance to 10.500-10.700 EPS.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $153.66 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock’s 50-day simple moving average is $159.39 and its 200-day simple moving average is $155.10. The firm has a market capitalization of $370.29 billion, a PE ratio of 23.11, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.38%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on JNJ. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Stifel Nicolaus dropped their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Barclays upped their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Bank of America cut their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, April 10th. Finally, Raymond James reduced their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $171.50.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Johnson & Johnson stock. Brighton Jones LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 13.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 51,876 shares of the company’s stock after acquiring an additional 6,332 shares during the quarter. Brighton Jones LLC’s holdings in Johnson & Johnson were worth $7,502,000 as of its most recent filing with the SEC. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.